Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Generic name: panobinostat lactate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 12, 2026
Generic Entry Controlled by: Argentina Patent 61,297

FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.

This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK

See drug price trends for FARYDAK.

The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.

Generic name: vortioxetine hydrobromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 16, 2026
Generic Entry Controlled by: Argentina Patent 61,481
Patent Title: COMPUESTOS CON ACTIVIDAD COMBINADA SOBRE SERT, 5-HT3 Y 5-HT1A

TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.

Generic name: vortioxetine hydrobromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 16, 2026
Generic Entry Controlled by: Argentina Patent 65,797
Patent Title: USOS Y DERIVADOS DE 1-(2- (2,4- DIMETILFENILSULFANIL) FENIL) PIPERAZINA

TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.

Generic name: safinamide mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2026
Generic Entry Controlled by: Argentina Patent 61,510

XADAGO is a drug marketed by Mdd Us. There are three patents protecting this drug.

This drug has ninety-seven patent family members in thirty-one countries. There has been litigation on patents covering XADAGO

See drug price trends for XADAGO.

The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the safinamide mesylate profile page.

Generic name: daprodustat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2026
Generic Entry Controlled by: Argentina Patent 61,570
Patent Title: COMPUESTO DE GLICINA SUSTITUIDO EN EL N HETEROAROMATICO COMPOSICION FARMACEUTICA QUE LO COMPRENDE, SU USO PARA PREPARAR UN MEDICAMENTO, PROCEDIMIENTOS PARA PREPARAR DICHA COMPOSICION FARMACEUTICA Y PARA PREPARAR EL COMPUESTO

JESDUVROQ is a drug marketed by Glaxosmithkline. There are six patents protecting this drug.

This drug has forty-four patent family members in thirty-one countries.

See drug price trends for JESDUVROQ.

The generic ingredient in JESDUVROQ is daprodustat. One supplier is listed for this generic product. Additional details are available on the daprodustat profile page.

Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2026
Generic Entry Controlled by: Argentina Patent 61,565

TEKTURNA HCT is a drug marketed by Noden Pharma. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering TEKTURNA HCT

See drug price trends for TEKTURNA HCT.

The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

Generic name: amlodipine besylate; hydrochlorothiazide; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2026
Generic Entry Controlled by: Argentina Patent 61,627

EXFORGE HCT is a drug marketed by Novartis.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering EXFORGE HCT

See drug price trends for EXFORGE HCT.

The generic ingredient in EXFORGE HCT is amlodipine besylate; hydrochlorothiazide; valsartan. There are fifty drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Argentina Patent 61,730

BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Argentina Patent 61,730

FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fourteen tentatively approved generics are ready to enter the market.

This drug has four hundred and twenty-five patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Argentina Patent 61,730

QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

Generic name: bosutinib monohydrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 29, 2026
Generic Entry Controlled by: Argentina Patent 54,505
Patent Title: FORMAS CRISTALINAS DE 4- ((2,4-DICLORO-5-METOXIFENIL) AMINO ) -6-METOXI-7-(3-(4-METIL-1-PIPERAZINIL) PROPOXI) -3- QUINOLINCARBONITRILO Y METODOS DE PREPARACION DE LAS MISMAS

BOSULIF is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and two Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has eighty-one patent family members in thirty countries. There has been litigation on patents covering BOSULIF

See drug price trends for BOSULIF.

The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the bosutinib monohydrate profile page.

Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: Argentina Patent 61,838
Patent Title: MODULADORES DE PROPIEDADES FARMACOCINETICAS DE TERAPEUTICOS

EVOTAZ is a drug marketed by Bristol. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ

See drug price trends for EVOTAZ.

The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.

Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: Argentina Patent 65,439
Patent Title: DERIVADOS DE TIAZOLES 1,3 NO CONDENSADOS,COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USOS COMO AGENTES ANTIVIRALES, EN PARTICULAR ANTI HIV.

EVOTAZ is a drug marketed by Bristol. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ

See drug price trends for EVOTAZ.

The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.

Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: Argentina Patent 67,412
Patent Title: MODULADORES DE PROPIEDADES FARMACEUTICAS DE PRODUCTOS TERAPEUTICOS

EVOTAZ is a drug marketed by Bristol. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ

See drug price trends for EVOTAZ.

The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.

Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: Argentina Patent 106,924
Patent Title: MODULADORES DE PROPIEDADES FARMACOCINÉTICAS DE TERAPÉUTICOS

EVOTAZ is a drug marketed by Bristol. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ

See drug price trends for EVOTAZ.

The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2026
Generic Entry Controlled by: Argentina Patent 61,989

EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2026
Generic Entry Controlled by: Argentina Patent 61,989

EPIDUO FORTE is a drug marketed by Galderma Labs.

This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

Generic name: simeprevir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 28, 2026
Generic Entry Controlled by: Argentina Patent 55,359
Patent Title: INHIBIDORES MACROCICLICOS DEL VIRUS DE LA HEPATITIS C

OLYSIO is a drug marketed by Janssen Prods. There are eight patents protecting this drug.

This drug has sixty-four patent family members in forty-one countries.

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

Generic name: daclatasvir dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 11, 2026
Generic Entry Controlled by: Argentina Patent 63,684
Patent Title: DERIVADOS DE 4, 4´-BIFENILDIILBIS(1H-IMIDAZOL-5, 2-DIIL) COMO INHIBIDORES DEL VIRUS DE LA HEPATITIS C, COMPOSICION QUE LOS COMPRENDE Y SU USO PARA TRATAR UNA INFECCION CON VHC.

DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug.

This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.

Generic name: daclatasvir dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 11, 2026
Generic Entry Controlled by: Argentina Patent 108,411
Patent Title: INHIBIDORES DEL VIRUS DE LA HEPATITIS C

DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug.

This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.

Generic name: ticagrelor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 21, 2026
Generic Entry Controlled by: Argentina Patent 62,451

BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has sixty-two patent family members in thirty-five countries. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ticagrelor profile page.

Generic name: macitentan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2026
Generic Entry Controlled by: Argentina Patent 62,501

OPSUMIT is a drug marketed by Actelion. There are five patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and one patent family members in thirty-five countries. There has been litigation on patents covering OPSUMIT

See drug price trends for OPSUMIT.

The generic ingredient in OPSUMIT is macitentan. There are ten drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the macitentan profile page.

Generic name: seladelpar lysine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 13, 2026
Generic Entry Controlled by: Argentina Patent 58,044

LIVDELZI is a drug marketed by Gilead Sciences Inc. There are six patents protecting this drug.

This drug has one hundred and thirty-eight patent family members in forty-six countries.

The generic ingredient in LIVDELZI is seladelpar lysine. One supplier is listed for this generic product. Additional details are available on the seladelpar lysine profile page.

Generic name: lenalidomide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: Argentina Patent 57,868
Patent Title: METODOS EN LOS QUE SE USA 3-(4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL)-PIPERIDIN-2,6-DIONA PARA EL TRATAMIENTO DE CIERTAS LEUCEMIAS

REVLIMID is a drug marketed by Bristol Myers Squibb. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has three hundred and thirty-one patent family members in forty-one countries. There has been litigation on patents covering REVLIMID

See drug price trends for REVLIMID.

The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the lenalidomide profile page.

Generic name: sacubitril; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2026
Generic Entry Controlled by: Argentina Patent 57,882
Patent Title: COMPUESTOS DE ACCION DOBLE DE BLOQUEADORES DEL RECEPTOR DE ANGIOTENSINA E INHIBIDORES DE ENDOPEPTIDASA NEUTRA

ENTRESTO SPRINKLE is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and eight patent family members in thirty-nine countries. There has been litigation on patents covering ENTRESTO SPRINKLE

See drug price trends for ENTRESTO SPRINKLE.

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.

Generic name: betrixaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Argentina Patent 56,787
Patent Title: SALES Y POLIMORFOS FARMACEUTICOS DE UN INHIBIDOR DEL FACTOR XA

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

Generic name: metformin hydrochloride; rosiglitazone maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Argentina Patent 57,970
Patent Title: COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE LA DIABETES MELLITUS Y CONDICIONES ASOCIADAS CON LA DIABETES MELLITUS Y PROCEDIMIENTOS PARA PREPRAR DICHAS COMPOSICIONES

AVANDAMET is a drug marketed by Sb Pharmco.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering AVANDAMET

The generic ingredient in AVANDAMET is metformin hydrochloride; rosiglitazone maleate. There are forty-nine drug master file entries for this API. Additional details are available on the metformin hydrochloride; rosiglitazone maleate profile page.

Generic name: bedaquiline fumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Argentina Patent 64,149

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

This drug has ninety-seven patent family members in thirty-nine countries.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.

Generic name: ceritinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Argentina Patent 64,197

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.

Generic name: ceritinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Argentina Patent 77,849

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.

Generic name: ceritinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Argentina Patent 107,966

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.

Generic name: telotristat etiprate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Argentina Patent 64,279

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

This drug has seventy patent family members in twenty-nine countries.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.

Generic name: abacavir sulfate; lamivudine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 02, 2027
Generic Entry Controlled by: Argentina Patent 59,120
Patent Title: SAL DE DICARBOXILATO DEL (1S,4R) -4- (2-AMINO-6- (CICLOPROPILAMINO ) -9H- PURIN-9-IL)-2- CICLOPENTEN -1- METANOL Y PROCEDIMIENTO PARA SU PREPARACION

EPZICOM is a drug marketed by Viiv Hlthcare. Five tentatively approved generics are ready to enter the market.

This drug has seventy patent family members in twenty-nine countries. There has been litigation on patents covering EPZICOM

See drug price trends for EPZICOM.

The generic ingredient in EPZICOM is abacavir sulfate; lamivudine. There are twelve drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the abacavir sulfate; lamivudine profile page.

Generic name: abacavir sulfate; lamivudine; zidovudine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 02, 2027
Generic Entry Controlled by: Argentina Patent 59,120
Patent Title: SAL DE DICARBOXILATO DEL (1S,4R) -4- (2-AMINO-6- (CICLOPROPILAMINO ) -9H- PURIN-9-IL)-2- CICLOPENTEN -1- METANOL Y PROCEDIMIENTO PARA SU PREPARACION

TRIZIVIR is a drug marketed by Viiv Hlthcare. One tentatively approved generic is ready to enter the market.

This drug has seventy patent family members in twenty-nine countries. There has been litigation on patents covering TRIZIVIR

See drug price trends for TRIZIVIR.

The generic ingredient in TRIZIVIR is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this API. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.

Generic name: abiraterone acetate; niraparib tosylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2027
Generic Entry Controlled by: Argentina Patent 64,777

AKEEGA is a drug marketed by Janssen Biotech. There are thirteen patents protecting this drug.

This drug has three hundred and fourteen patent family members in fifty-seven countries. There has been litigation on patents covering AKEEGA

See drug price trends for AKEEGA.

The generic ingredient in AKEEGA is abiraterone acetate; niraparib tosylate. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the abiraterone acetate; niraparib tosylate profile page.

Generic name: niraparib tosylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2027
Generic Entry Controlled by: Argentina Patent 64,777

ZEJULA is a drug marketed by Glaxosmithkline. There are eight patents protecting this drug.

This drug has two hundred and eighty-five patent family members in fifty-five countries. There has been litigation on patents covering ZEJULA

See drug price trends for ZEJULA.

The generic ingredient in ZEJULA is niraparib tosylate. One supplier is listed for this generic product. Additional details are available on the niraparib tosylate profile page.

Generic name: alogliptin benzoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Argentina Patent 65,096
Patent Title: PREPARACION SOLIDA

NESINA is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-nine patent family members in thirty-seven countries. There has been litigation on patents covering NESINA

See drug price trends for NESINA.

The generic ingredient in NESINA is alogliptin benzoate. There are ten drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate profile page.

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Argentina Patent 65,097

OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Argentina Patent 65,405

PANCREAZE is a drug marketed by

This drug has one hundred and one patent family members in forty-two countries.

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: esomeprazole magnesium; naproxen
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Argentina Patent 59,589
Patent Title: PROCESO PARA LA PREPARACION DE SAL DE MAGNESIO DE TRIHIDRATO DE S-OMEPRAZOL, SAL DE POTASIO DE S-OMEPRAZOL INTERMEDIARIA Y PROCESO PARA PREPARARLA

VIMOVO is a drug marketed by Horizon. One tentatively approved generic is ready to enter the market.

This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering VIMOVO

See drug price trends for VIMOVO.

The generic ingredient in VIMOVO is esomeprazole magnesium; naproxen. There are seventy-four drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the esomeprazole magnesium; naproxen profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Argentina Patent 65,405

ZENPEP is a drug marketed by

This drug has one hundred and one patent family members in forty-two countries.

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: rolapitant hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: Argentina Patent 65,802
Patent Title: FORMULACIONES DE COMPRIMIDOS QUE CONTIENEN SALES DE 8- [( 1- ( 3,5- BIS- (TRIFLUOROMETIL) FENIL) -ETOXI ) - METIL) -8- FENIL -1, 7- DIAZA- SPIRO [ 4,5] DECAN -2- ONA Y COMPRIMIDOS ELABORADOS A PARTIR DE ESTAS

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

This drug has one hundred and fifty-eight patent family members in thirty-five countries.

The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.

Generic name: maraviroc
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 27, 2027
Generic Entry Controlled by: Argentina Patent 60,159
Patent Title: COMBINACIONES DE COMPUESTOS DERIVADOS DE TROPANO UTILES EN TERAPIA

SELZENTRY is a drug marketed by Viiv Hlthcare. One tentatively approved generic is ready to enter the market.

This drug has one hundred and fifty-eight patent family members in thirty-five countries.

See drug price trends for SELZENTRY.

The generic ingredient in SELZENTRY is maraviroc. There are two drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the maraviroc profile page.

Generic name: azilsartan kamedoxomil
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Argentina Patent 65,850
Patent Title: COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE UN DERIVADO DE BENZIMIDAZOL-7-CARBOXILATO Y UN AGENTE DE CONTROL DE PH

EDARBI is a drug marketed by Azurity. There is one patent protecting this drug.

This drug has twenty-one patent family members in seventeen countries. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. There are six drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the azilsartan kamedoxomil profile page.

Generic name: axitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Argentina Patent 65,931

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has ninety-seven patent family members in thirty countries. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the axitinib profile page.

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Argentina Patent 59,656
Patent Title: COMPRIMIDO FARMACEUTICO QUE COMPRENDE LA SAL DE BIS - (MONOETANOLAMINA) DEL ACIDO 3' -[(2Z )-[1-(3,4- DIMETILFENIL)-1,5- DIHIDRO-3- METIL-5 OXO- 4H-PIRAZOL-4- ILIDENO} HIDRAZINO} -2' HIDROXI- { 1,1'- BIFENIL]-3- CARBOXILICO [ELTROMBOPAG OLAMINA), CAPSULA FARMACEUTICA, FORMA DE DOSIFICACION Y GRANULO

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Argentina Patent 107,711
Patent Title: COMPRIMIDO FARMACÉUTICO, GRÁNULOS FARMACÉUTICOS Y PROCEDIMIENTO PARA SU PREPARACIÓN, FORMA FARMACÉUTICA ORAL SÓLIDA, CÁPSULA

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 05, 2027
Generic Entry Controlled by: Argentina Patent 61,233
Patent Title: FORMULACION DE LIBERACION PROLONGADA DE NALTREXONA

CONTRAVE is a drug marketed by Nalpropion. There are eighteen patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and twenty-seven patent family members in forty-five countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: deoxycholic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Argentina Patent 67,440
Patent Title: ÁCIDO BILIAR SINTETICO, UNA COMPOSICION QUE LO COMPRENDE, UN METODO PARA SU PREPARACION, COMPUESTOS INTERMEDIARIOS DE SíNTESIS Y SU EMPLEO EN LA ELIMINACION DE LOS DEPoSITOS DE GRASA CORPORAL

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.

Generic name: deoxycholic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Argentina Patent 112,325
Patent Title: MÉTODO DE PREPARACIÓN DEL ÁCIDO BILIAR SINTÉTICO

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Argentina Patent 66,543
Patent Title: DERIVADOS DE PIRIDAZINONA

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.

This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Argentina Patent 67,505
Patent Title: DERIVADOS DE PIRIMIDINIL-PIRIDAZINONA

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.

This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Argentina Patent 67,557
Patent Title: PREPARACION SOLIDA Y METODO DE PREPARACION

KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has ninety patent family members in forty-one countries. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. There are ten drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

Generic name: clascoterone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Argentina Patent 111,202
Patent Title: FORMAS CRISTALINAS DE CORTEXOLONA

WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty countries. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.

Generic name: clascoterone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Argentina Patent 111,351
Patent Title: FORMA CRISTALINA I DEL 17-a-PROPIONATO DE CORTEXOLONA, COMPOSICIÓN FARMACÉUTICA QUE LA CONTIENE Y SU EMPLEO EN EL TRATAMIENTO DE UNA PATOLOGÍA RELACIONADA CON EL APARATO UROGENITAL, ENDÓCRINO O DE LA PIEL Y/O ANEXOS DE ÉSTA

WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty countries. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.